Cochlear Limited (ASX: COH) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Cochlear Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Cochlear Limited (ASX: COH)
Latest News
Share Gainers
The Cochlear share price is now up 25% since it announced its US$268 million bill for damages
⏸️ ASX Shares
Where to invest $10,000 in the ASX 200 in February
⏸️ Investing
Why I think the dip in the ResMed Inc share price is great news for new investors
Share Fallers
Why the ResMed share price is getting smoked
Growth Shares
Why the Volpara share price plunged 15% lower today
⏸️ Best ASX Shares
Happy Australia Day!
Share Market News
ASX 200 lunch time report: Cochlear, Telstra & Woolworths higher
⏸️ ASX Shares
How to turn $50,000 into $700,000 on the Australian share market
Growth Shares
2 ASX shares that every investor should own
Growth Shares
3 ASX healthcare shares to bring your portfolio to life
Growth Shares
3 top buy and hold ASX healthcare shares to buy today
⏸️ Famous Investors
Top fund manager names 12 ASX shares for a recession proof portfolio
Frequently Asked Questions
-
Yes, Cochlear Ltd has historically paid two fully franked dividends a year.
-
Cochlear Ltd generally pays its dividends in April and October.
-
Cochlear Ltd listed on the ASX on 4 December 1995.
COH ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Cochlear Limited
Cochlear Ltd (ASX: COH) is the world's leading cochlear implant device manufacturer with around half of global market share.
The company was founded in Australia in 1983 to commercialise implants pioneered by Melbourne researcher Dr Graeme Clark, but later became a separate entity.
Developed markets contribute the bulk of Cochlear's group revenue with cochlear implants the standard of care for children with severe to profound hearing loss. The company is also catering for a growing cohort of seniors when standard hearing aid technology loses its effectiveness.
Cochlear's main products include cochlear implants, bone-anchored hearing devices, and associated sound processors. The vast majority of Cochlear's revenue is derived from overseas, with the US and Europe by far the company's two largest markets.
